
A normal lactate and nonspecific histopathology do not exclude TK2D in adults. Retrieving stored muscle tissue for mitochondrial DNA studies can reach a diagnosis when initial biopsy analysis falls short.
Professor of neurology at Columbia University Irving Medical Center.

A normal lactate and nonspecific histopathology do not exclude TK2D in adults. Retrieving stored muscle tissue for mitochondrial DNA studies can reach a diagnosis when initial biopsy analysis falls short.

Approval shifts access from research programs to insurance review and specialty pharmacy. Honest counseling about realistic goals, and about the value of early treatment, helps families engage with therapy.

Pooled safety data show most adverse events resolve with dose reduction rather than discontinuation. Interpreting transaminase elevations requires separating muscle sources from liver sources in patients who already have myopathy.

Weight-based escalation, G-tube administration, and careful attribution of gastrointestinal symptoms help patients stay on therapy. One case shows diarrhea traced to tube feeds rather than the drug.

Supportive care improves quality of life without halting progression. Replacing the depleted nucleotide pool shows longer survival and a notable chance of regaining lost motor milestones in pooled data.

Tissue studies can confirm or challenge sequencing results, but access and time drive test choice. The panel explains when a biopsy helps and why stopping at a panel is not enough.

A shortened diagnostic odyssey depends on recognizing red flags such as small stature and gastrointestinal symptoms, then moving promptly to exome or genome sequencing with careful, planned delivery of results.

A four-year-old with regression, ptosis, and feeding problems illustrates the textbook features of severe early-onset TK2D and the laboratory and genetic findings that confirm the diagnosis.

Untreated survival ranges from about one year to two decades by onset age. Disease biology explains why muscle fails first, and early attention to swallowing and nutrition shapes outcomes.

Age at symptom onset is the strongest determinant of severity in TK2 deficiency. The panel defines the disease, its prevalence, and the presenting features that distinguish infantile, childhood, and late-onset patients.

The professor of neurology at Columbia University Irving Medical Center highlighted the decades of research collaboration for patients with neuromuscular disease at the 2026 MDA conference.